Incidence, Risk Factors, and Prevention of Post-ERCP Pancreatitis

Gastroenterology Clinics of North America

Volumn 36, Issue 2, 2007, Pages 259-276

  Cooper, Scott T ^a   Slivka, Adam ^a  

^a PRESBYTERIAN UNIVERSITY HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLCYSTEINE; ALLOPURINOL; ANTIBIOTIC AGENT; CALCIUM CHANNEL BLOCKING AGENT; CORTICOSTEROID; DICLOFENAC; GABEXATE; GLYCERYL TRINITRATE; HEPARIN; INTERLEUKIN 10; LIDOCAINE; OCTREOTIDE; PLACEBO; SOMATOSTATIN; THROMBOCYTE ACTIVATING FACTOR; ULINASTATIN;

CLINICAL TRIAL; ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY; ENDOSCOPY; HUMAN; INCIDENCE; META ANALYSIS; PANCREATITIS; REVIEW; RISK FACTOR; SYSTEMATIC REVIEW;

ANTI-INFLAMMATORY AGENTS; CHOLANGIOPANCREATOGRAPHY, ENDOSCOPIC RETROGRADE; HUMANS; INCIDENCE; PANCREATITIS; POSTOPERATIVE COMPLICATIONS; RISK FACTORS; WORLD HEALTH;

EID: 34249111877     PISSN: 08898553     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.gtc.2007.03.006     Document Type: Review

References (47)

1. Freeman M.L., Disario J.A., Nelson D.B., et al. Risk factors for post-ERPC pancreatitis: a prospective, multicenter study. Gastrointest Endosc 54 (2001) 425-434
2. Freeman M.L., Nelson D.B., Sherman S., et al. Complications of endoscopic biliary sphincterotomy. N Engl J Med 335 (1996) 909-918
3. Andriulli A., Clemente R., Solmi L., et al. Gabexate or somatostatin administration before ERCP in patients at high risk for post-ERCP pancreatitis: a multicenter, placebo-controlled, randomized clinical trial. Gastrointest Endosc 55 (2002) 488-495
4. Chistoforidis E., Goulimaris I., Kanellos I., et al. Post-ERCP pancreatitis and hyperamylasemia: patient-related and operative risk factors. Endoscopy 34 (2002) 286-292
5. Masci E., Toti G., Mariani A., et al. Complications of diagnostic and therapeutic ERCP: a prospective multicenter study. Am J Gastroenterol 96 (2001) 417-423
6. Vandervoort J., Soetikno R.M., Tham T.C., et al. Risk factors for complications after performance of ERCP. Gastrointest Endosc 56 (2002) 652-656
7. Chi-Liang C., Sherman S., Watkins J., et al. Risk factors for Post-ERCP pancreatitis: a prospective multicenter study. Am J Gastroenterol 101 (2006) 139-147
8. Cotton P.B., Lehman G., Vennes J., et al. Endoscopic sphincterotomy complications and their management: an attempt at consensus. Gastrointest Endosc 37 (1991) 383-393
9. Bradley III E.L. A clinically based classification system for acute pancreatitis. Summary of the international symposium on Acute Pancreatitis, Atlanta (GA), September 11 through 13, 1992. Arch Surg 128 (1993) 586-590
10. Cohen S., Bacon B.R., Berlin J.A., et al. National Institutes of Health State-of-the-Science Conference Statement: ERCP for diagnosis and therapy, January 14-16. Gastrointest Endosc 56 (2002) 803-809
11. Sherman S., Troiano F.P., Hawes R.H., et al. Sphincter of Oddi manometry: decreased risk of clinical pancreatitis with the use of a modified aspirating catheter. Gastrointest Endosc 36 (1990) 462-466
12. Sherman S., Blaut U., Watkins J.L., et al. Does prophylactic administration of corticosteroid reduce the risk and severity of post-ERCP pancreatitis: a randomized, prospective, multicenter study. Gastrointest Endosc 58 (2003) 23-29
13. Masci E., Mariani A., Curioni S., et al. Risk factors for pancreatitis following endoscopic retrograde cholangiopancreatography: a meta-analysis. Endoscopy 35 (2003) 830-834
14. Cheon Y., Fogel E., McHenry L., et al. Frequency and severity of post-ERCP pancreatitis correlated with extent of pancreatic ductal opacification. Gastrointest Endosc 65 (2007) [abstract 85]
15. Rabenstein T., Ruppert T., Schneider H.T., et al. Benefits and risks of needle-knife papillotomy. Gastrointest Endosc 46 (1997) 207-211
16. Tssujino T., Kawabe T., Komatsu Y., et al. Endoscopic papillary balloon dilation for bile duct stones: immediate and long-tem outcome in 1000 patients. Clin Gastroenterol Hepatol 1 (2007) 130-137
17. Fazel A., Quadri A., Catalano M., et al. Does a pancreatic stent prevent post-ERCP pancreatitis? A prospective randomized study. Gastrointest Endosc 87 (2003) 291-294
18. Singh P., Das A., Isenberg G., et al. Does prophylactic pancreatic stent placement reduce the risk of post-ERCP acute pancreatitis? A meta-analysis of controlled trials. Gastrointest Endosc 60 (2004) 544-550
19. Freeman M.L., Overby C., and Qi D. Pancreatic stent insertion: consequences of failure and results of a modified technique to maximize success. Gastrointest Endosc 59 (2004) 8-14
20. Elta G.H., Barnett J.L., Wille R.T., et al. Pure cut electrocautery current for sphincterotomy causes less post-procedure pancreatitis than blended current. Gastrointest Endosc 47 (1998) 149-153
21. Macintosh D.G., Love J., and Abraham N. Endoscopic sphincterotomy by using a pure-cut electrosurgical current and the risk of post-ERCP pancreatitis: a prospective randomized trial. Gastrointest Endosc 60 (2004) 551-556
22. Perini R.F., Sadurski R., Cotton P.B., et al. Post-sphincterotomy bleeding after the introduction of microprocessor-controlled electrosurgery: does the new technology make a difference?. Gastrointest Endosc 61 (2005) 53-57
23. Lella F., Bagnolo F., Colombo E., et al. A simple was of avoiding post-ERCP pancreatitis. Gastrointest Endosc 59 (2004) 830-834
24. Cavallini G., Tittobello A., Frulloni L., et al. Gabexate for the prevention of pancreatic damage related to endoscopic retrograde cholangiopancreatography. Gabexate in digestive endoscopy-Italian Group. N Engl J Med 335 (1996) 919-923
25. Deviere J., Le Moine O., Van Laethem J.L., et al. Interleukin 10 reduces the incidence of pancreatitis after therapeutic endoscopic retrograde cholangiopancreatography. Gastroenterology 120 (2001) 498-505
26. Dumot J.A., Conwell D.L., Zuccaro Jr. G., et al. A randomized, double blind study of interleukin 10 for the prevention of ERCP-induced pancreatitis. Am J Gastroenterol 96 (2001) 2098-2102
27. Sherman S., Lehman G., Geenen J.E., et al. Evaluation of recombinant human platelet activating factor acetylhydolase (RPAF-AH) for reducing the incidence and severity of post-ERCP acute pancreatitis. [abstract]. Gastrointest Endosc 51 (2000) [AB67]
28. George S., Kulkarni A.A., Stevens G., et al. Role of osmolality of contrast media in the development of post-ERCP pancreatitis. Dig Dis Sci 49 (2004) 503-508
29. Xiong G.S., Wu S.M., Zhang X.W., et al. Clinical trial of gabexate in the prophylaxis of post-endoscopic retrograde cholangiopancreatography pancreatitis. Braz J Med Biol Res 39 (2006) 85-90
30. Fujishiro H., Adachi K., Imaoka T., et al. Ulinastatin shows preventive effect on post-endoscopic retrograde cholangiopancreatography pancreatitis in a multicenter prospective randomized study. J Gastroenterol Hepatol 21 (2006) 1065-1069
31. Arvanitidis D., Anagnostopoulos G.K., Giannopoulos D., et al. Can somatostatin prevent post-ERCP pancreatitis? Results of a randomized controlled trial. J Gastroenterol Hepatol 19 (2004) 278-282
32. Li A., Pan X., Zhang W., et al. Effect of octreotide administration in the prophylaxis of post-ERCP pancreatitis and hyperamylasemia: a multicenter, placebo-controlled, randomized clinical trial. Am J Gastroenterol 102 (2007) 46-51
33. Thomopoulos K.C., Pagoni N., Vagenas K.A., et al. Twenty-four hour prophylaxis with increased dosage of octreotide reduces the incidence of post-ERCP pancreatitis. Gastrointest Endosc 64 (2006) 726-731
34. Andriulli A., Leandro G., Niro G., et al. Pharmacologic treatment can prevent pancreatic injury after ERCP: a meta-analysis. Gastrointest Endosc 51 (2000) 1-7
35. Murray B., Carter R., Imrie C., et al. Diclofenac reduces the incidence of acute pancreatitis after endoscopic retrograde cholangiopancreatography. Gastroenterology 124 (2003) 1786
36. Raty S., Sand J., Pulkkinen M., et al. Post-ERCP pancreatitis: reduction by routine antibiotics. J Gastrointest Surg 5 (2001) 339-345
37. Schwartz J.J., Lew R.J., Ahmad N.A., et al. The effect of lidocaine sprayed on the major duodenal papilla on the frequency of post-ERCP pancreatitis. Gastrointest Endosc 59 (2004) 179-184
38. Sand J., and Nordback I. Prospective randomized trial of the effect of nifedipine on pancreatic irritation after endoscopic retrograde cholangiopancreatography. Digestion 54 (1993) 105-111
39. Prat F., Amaris J., Ducot B., et al. Nifedipine for prevention of post-ERCP pancreatitis: a prospective, double-blind randomized study. Gastrointest Endosc 56 (2002) 202-208
40. Kaffes A.J., Bourke M.J., Ding S., et al. A prospective, randomized, placebo-controlled trial of transdermal glycerol trinitrate in ERCP: effect on technical success and post-ERCP pancreatitis. Gastrointest Endosc 64 (2006) 351-357
41. Karsinelos P., Kountouras J., Paroutoglou G., et al. Intravenous N-acetylcysteine does not prevent post-ERCP pancreatitis. Gastrointest Endosc 62 (2005) 105-111
42. Mosler P., Sherman S., Marks J., et al. Oral allopurinol does not prevent the frequency or the severity of post-ERCP pancreatitis. Gastrointest Endosc 62 (2005) 245-250
43. Budzynska A., Marek T., Nowak A., et al. A prospective, randomized, placebo-controlled trial of prednisone and allopurinol in the prevention of ERCP-induced pancreatitis. Endoscopy 33 (2001) 766-772
44. Katsinelos P., Kountouras J., Chatzis J., et al. High-dose allopurinol for the prevention of post-ERCP pancreatitis: a prospective randomized double-blind controlled trial. Gastrointest Endosc 61 (2005) 407-415
45. Rabenstein T., Fischer B., Wiessner V., et al. Low-molecular-weight-heparin hepatin does not prevent acute post-ERCP pancreatitis. Gastrointest Endosc 59 (2004) 606-613
46. Dumot J.A., Conwell D.L., O'Connor J.B., et al. Pretreatment with methylprednisolone to prevent ERCP-induced pancreatitis: a randomized, multicenter, placebo-controlled clinical trial. Am J Gastroenterol 93 (1998) 61-65
47. Papachristou G.I., Sass D.A., Avula H., et al. Is the monocyte chemotactic protein-1 -2518 G allele a risk factor for severe acute pancreatitis. Clin Gastroenterol Hepatol 3 (2005) 475-481